-
Guangdong Accelerates Centralized Procurement for Apixaban and Key Therapeutics
•
The Guangdong Drug Trading Center has issued a critical update on preparations for the centralized volume-based procurement (VBP) of Apixaban Tablets and related medications under the Guangdong Alliance framework. This initiative, aligned with provincial healthcare policies (Yue Medical Insurance Letter [2025] No. 49), mandates streamlined logistics and supply chain coordination…
-
Shanghai Designates Backup Suppliers and Specialized Drug Formulations in GY-YD2024-2 Procurement
•
Shanghai has finalized its list of second-tier backup suppliers and manufacturers for specialized drug formulations under the 10th National VBP (Volume-Based Procurement) Program (GY-YD2024-2). The move aims to stabilize supply chains, address market shortages of irregular drug specifications, and ensure cost-effective access to critical medications. Key suppliers include domestic pharmaceutical…
-
HMZS Biopharmaceutical Blacklisted After Failing to Monitor Production Process
•
HMZS Biopharmaceutical, a Chinese company that won a bid for its phloroglucinol in the 10th volume-based procurement (VBP) tender round, has been blacklisted by the National Drug Alliance Procurement Office. The company’s entrusted manufacturer, Taiji Group Sichuan Taiji Pharmaceutical Co. Ltd., was also blacklisted following the incident. Reason for BlacklistingThe…
-
National Allied Procurement Office Allows VBP Winners to Adjust MAH and Manufacturing Details
•
The National Allied Procurement Office has issued a notification clarifying rules for China’s Volume-Based Procurement (VBP) tender program, allowing winning manufacturers to modify key details such as the marketing authorization holder (MAH), manufacturing company, packaging specs, and supply arrangements under specific conditions. The changes aim to maintain supply stability while…
-
China’s Drug Procurement Under Scrutiny: Addressing Quality Concerns and Policy Reforms
•
An In – Depth Exploration of the Recent Survey on Bulk Drug Procurement in China and the Responses to Public ConcernsIn January of this year, concerns were raised by some experts about the potential quality risks of certain drugs under the centralized bulk procurement system in China, such as “ineffective…
-
NHSA Seeks Expert Opinions on VBP Drug Quality and Efficacy
•
The National Healthcare Security Administration (NHSA) has released a letter titled “Letter on Requesting Assistance in Hearing Opinions on Volume-based Procurement (VBP) of Drugs Face to Face.” The NHSA will visit Shanghai to listen to the opinions and suggestions of relevant committee members and experts on VBP policy and the…
-
10th National VBP Round Results Announced: Contracts Worth Over RMB1.3 Billion
•
The national Volume-Based Procurement (VBP) authorities have released comprehensive details regarding the 10th VBP round, including volumes and regions awarded to winning bidders. According to Fineline Info & Tech‘s calculations, the full round, covering 196 companies with winning bids, was valued at over RMB1.3 billion (USD 178 million) in contracts.…
-
National VBP Program Round 10: 195 Manufacturers Secure Winning Bids for 62 Drugs
•
The preliminary outcomes of the 10th round of China’s national volume-based procurement (VBP) program were released, with a total of 195 drug manufacturers securing tender spots for 62 different drug products. There were no failed tenders in this round, and the official results are anticipated to be announced after December…
-
China’s NHSA and NHC Issue Guidelines to Enhance Volume-based Procurement Mechanism
•
The National Healthcare Security Administration (NHSA) and National Health Commission (NHC) of China have released the “Notice on Improving the Working Mechanism for Volume-based Procurement (VBP) and its Implementation.” The notice outlines refined measures for hospital access, use, monitoring, examination, and feedback in relation to VBP drugs and consumables. Urging…
-
Hefan Medicine’s Piracetam Production and Marketing Suspended Over GMP Violations
•
The National Drug Alliance Procurement Office has issued a notification to suspend the manufacturing and marketing of piracetam by Zhuhai Hefan Medicine Co., Ltd. The suspension comes as a result of severe defects found in the company’s manufacturing management process, which are in direct violation of the Good Manufacturing Practice…
-
National Allied Procurement Office Announces Round 10 VBP Tender Program with New Rules
•
The National Allied Procurement Office has released a notification regarding Round 10 of the national Volume-Based Procurement (VBP) tender program, which is scheduled to take place in Shanghai on December 12. Eligible manufacturers are required to submit information related to drug varieties via the National Medical Products Administration (NMPA) website…
-
China’s National Allied Procurement Office Launches 10th VBP Tender Round Information Filing
•
The National Allied Procurement Office has released a notification initiating the information filing process for drugs selected in the 10th national volume-based procurement (VBP) tender round. This marks another step in China’s ongoing efforts to streamline drug procurement and ensure accessibility. Information Filing Process and RequirementsEnterprises are required to log…
-
Hunan Province Launches Pilot Program for Retail Sales of VBP Drugs with Strict Guidelines
•
The Hunan Healthcare Security Administration has released the “Pilot Implementation Plan for Volume-based Procurement (VBP) Drugs to Be Sold in Retail Pharmacies in Hunan Province,” outlining a strategic approach to integrating VBP drugs into the retail pharmacy landscape. The plan mandates the selection of at least one county (city) and…
-
Shanxi Province Announces Historic Drug Procurement Batch with 81 Products for 2024
•
On October 16, 2024, Shanxi Province’s drug procurement platform announced a notice regarding the submission of demand quantities for the tenth batch of national centralized drug procurement, with a record 81 drugs (263 specifications) making the list. This is poised to set a new record for the highest number of…
-
Shanghai Medical Procurement Platform Sets Price Cap for Non-Locally Supplied Drugs
•
Shanghai’s Sunshine Medical Procurement All-In-One (SMPA) has issued a notification concerning the online procurement prices for drugs from the first to seventh round of volume-based procurement (VBP) that are not primarily supplied in Shanghai. The notification mandates that these drugs’ prices should not exceed 1.5 times the winning prices or…
-
China’s VBP Office Exposes Collusion Among Six Firms in Bromhexine Bidding Process
•
The National Drug Alliance Procurement Office, which oversees the Volume-Based Procurement (VBP) program, has issued a statement revealing that six pharmaceutical firms were found to have engaged in collusion during the VBP bidding process for bromhexine in the 7th national tender. The implicated companies are Chengdu Xinjie Hi-tech Development Co.,…
-
Shaanxi Leads New Provincial Alliance for Volume-Based Procurement of Medical Products
•
The Shaanxi Public Resources Trading Center has announced the formation of a provincial alliance for volume-based procurement (VBP), with Shaanxi taking the lead. The alliance includes participants from Heilongjiang, Anhui, Jiangxi, Henan, Hubei, Hunan, Guangxi, Guizhou, Tibet, Qinghai, Ningxia, and Xinjiang, along with the Xinjiang Construction Corps. The alliance’s tender…
-
Yipinhong Pharmacy Repays $36.7 Million in Bromhexine Marketing Settlement
•
Yipinhong Pharmacy Co., Ltd (SHE: 300723), a China-based pharmaceutical company, has made a significant repayment of RMB 266.44 million (USD 36.7 million) to undisclosed buyers as part of a settlement for damages related to the marketing of bromhexine. The company admitted to engaging in anti-competitive practices by ‘colluding with other…
-
Shenzhen’s Draft Proposal for VBP Drug Procurement and Medical Insurance Fund Management Released
•
The Healthcare Security Administration (HSA) Bureau of the Shenzhen municipality has released a “Shenzhen Drug Volume-based Procurement (VBP) Medical Insurance Fund Balance Retention Management Measures (draft proposal)” and is soliciting public feedback until June 13, 2024. This document will apply to all VBP drugs with purchase agreements expiring this year…
-
Beijing Unveils Action Plan to Boost Pharmaceutical and Health Industry by 2026
•
The Beijing People’s Government has issued an “Action Plan” outlining measures and targets to “Accelerate Collaborative Innovation in Medicine and Health” over a three-year period from 2024 to 2026. Many of these measures were previously outlined in a draft document reported in April 2024. The plan sets an ambitious goal…
